Why Stroke Prevention in Atrial Fibrillation Matters More Than You Think
If you or someone you love has been diagnosed with atrial fibrillation — commonly called AFib — one of the first conversations your cardiologist likely had with you was about stroke risk. That conversation matters enormously. AFib increases the risk of stroke roughly fivefold compared to someone with a normal heart rhythm. The reason is straightforward: when the upper chambers of the heart quiver instead of contracting effectively, blood can pool and form clots. If one of those clots travels to the brain, the result is a stroke.
For decades, the standard approach to reducing that risk has been blood-thinning medication — first warfarin (Coumadin), and more recently direct oral anticoagulants like apixaban (Eliquis) or rivarelbixin (Xarelto). These drugs are effective. They reduce stroke risk in AFib patients by approximately 60 to 70 percent. But they come with a real trade-off: bleeding. For some patients, that trade-off becomes untenable.
This is where left atrial appendage closure enters the picture — and specifically, the Watchman device, which has fundamentally changed how we think about stroke prevention in a specific subset of AFib patients. As a structural and interventional cardiologist, I perform these procedures and counsel patients through this decision regularly. I want to give you a clear, honest picture of what LAAC involves, who it helps, and what it does not do.
What Is Left Atrial Appendage Closure and How Does the Watchman Device Work?
The left atrial appendage (LAA) is a small, finger-like pouch that protrudes from the left atrium of the heart. In patients with AFib, roughly 90 percent of stroke-causing clots originate in this structure. The logic behind left atrial appendage closure is simple: if you can seal off the appendage, you can dramatically reduce the source of those clots — and potentially eliminate the need for long-term blood thinners.
The Watchman device is a small, umbrella-shaped implant made of a nickel-titanium frame covered with a fabric membrane. During the procedure, I guide the device through a catheter inserted in the femoral vein (in the groin), advance it through the heart's septum into the left atrium, and deploy it at the opening of the appendage. The entire procedure typically takes 60 to 90 minutes under general anesthesia and requires a one-night hospital stay.
Over the following weeks, the heart's own tissue grows over the device, permanently sealing the appendage. Most patients take blood thinners for 45 days after implantation, then transition to dual antiplatelet therapy (aspirin plus clopidogrel) for six months, and eventually aspirin alone — or in some cases, no antithrombotic therapy at all.
The Data Behind the Watchman Device
The landmark trials that established the Watchman's role are PROTECT AF and PREVAIL, which compared the device to warfarin therapy. At five-year follow-up in PROTECT AF, LAAC for AFib with the Watchman demonstrated:
- A 40 percent relative reduction in all-cause mortality compared to warfarin
- A 60 percent reduction in cardiovascular and unexplained death
- Non-inferiority for stroke prevention, with superiority for hemorrhagic stroke reduction
More recent real-world registries, including data from over 38,000 patients in the NCDR LAAO Registry, have shown procedural success rates exceeding 98 percent and major complication rates below 2 percent. The device received FDA approval in 2015, and a newer generation — the Watchman FLX — offers improved conformability and a lower rate of peri-device leak.
These are meaningful numbers. But they require context, which is where the nuance of patient selection becomes critical.
Who Is a Good Candidate for LAAC for AFib — and Who Is Not?
This is the question I spend the most time on with patients, and it deserves a thorough answer. According to current ACC/AHA guidelines and the FDA-approved indication, the Watchman device is intended for patients who meet all three of the following criteria:
- Non-valvular atrial fibrillation — meaning AFib not caused by moderate-to-severe mitral stenosis or a mechanical heart valve
- Elevated stroke risk — typically a CHA₂DS₂-VASc score of 3 or higher (this score accounts for factors like age, hypertension, diabetes, prior stroke, heart failure, and vascular disease)
- A reasonable rationale for seeking a non-pharmacologic alternative to blood thinners — such as a history of major bleeding, high fall risk, occupation or lifestyle incompatible with anticoagulation, or documented intolerance
That third criterion is where clinical judgment matters most. The Watchman is not a convenience device. It is not for patients who simply dislike taking pills. The strongest candidates are those for whom blood thinners pose a genuine, documented risk — patients who have had gastrointestinal hemorrhage on anticoagulation, who have had intracranial bleeding, or who fall frequently and face a meaningful subdural hematoma risk.
If you are on a blood thinner and tolerating it well, with no bleeding complications, the evidence does not clearly favor switching to a device. This is an important distinction that sometimes gets lost in marketing.
Patients Who Need a More Nuanced Conversation
I also see patients referred for LAAC who have additional structural heart issues — significant mitral regurgitation, a patent foramen ovale, or prior cardiac surgery. These factors do not automatically disqualify someone, but they change the risk-benefit calculus and sometimes the procedural approach. If you have been told you need a Watchman and also have other heart conditions, it is worth having a comprehensive review of your imaging and clinical history. A second opinion from an experienced team can clarify whether LAAC is the right move or whether an alternative strategy — including surgical appendage exclusion during another planned procedure — makes more sense.
What to Expect During and After the Watchman Procedure
Patients understandably want to know what the experience is like. Here is a realistic overview:
Before the procedure: You will undergo a transesophageal echocardiogram (TEE) to assess the size and shape of your left atrial appendage and rule out any existing clots. If a clot is found, the procedure will be postponed. You will also have a detailed discussion about your current medications and any adjustments needed in the days leading up to implantation.
The day of: The procedure is performed in a cardiac catheterization lab under general anesthesia. You will have a catheter placed in your groin vein. I use fluoroscopy (live X-ray) and TEE guidance to position the device. Most patients are in the lab for about an hour. You will wake up in a recovery area and typically stay overnight for observation.
Recovery: Most patients go home the next day. Groin soreness is common for a few days. You should avoid heavy lifting or strenuous activity for about a week. The critical follow-up is a TEE at approximately 45 days post-procedure to confirm the device is properly seated and there is no significant leak around it. If everything looks good, your blood thinner is discontinued at that point.
Long-term: Once healed, the device requires no maintenance. There are no batteries, no moving parts, and it does not set off metal detectors. You will continue to see your cardiologist for routine AFib management, but the appendage closure itself is a one-time intervention.
Complications: What the Data Shows
No procedure is without risk. The major complications associated with Watchman implantation include:
- Pericardial effusion or tamponade (fluid or blood around the heart) — occurs in approximately 1 to 2 percent of cases, occasionally requiring drainage
- Device embolization (the device migrating from its position) — rare, occurring in less than 0.5 percent of cases with the newer Watchman FLX
- Peri-device leak — small residual leaks are seen in a minority of patients; most are clinically insignificant, but larger leaks may require continued anticoagulation or repeat intervention
- Stroke during the procedure — very uncommon, but a recognized risk of any left-heart catheterization
In experienced centers — those performing a high volume of structural heart procedures — complication rates are at the lower end of these ranges. This is one area where operator and institutional experience genuinely matters. If you are evaluating where to have this done, ask about case volume. Centers performing fewer than 25 to 50 cases per year may not have the same outcomes as high-volume programs.
Questions You Should Ask Before Agreeing to Left Atrial Appendage Closure
I encourage every patient considering LAAC for AFib to ask their cardiologist the following:
- What is my CHA₂DS₂-VASc score, and what does it mean for my personal stroke risk? — You can also estimate your surgical risk profile with our free cardiac surgery risk calculator to better understand your overall cardiac risk.
- Why is LAAC being recommended over continued anticoagulation in my specific case? — The answer should be specific to your history, not generic.
- How many of these procedures has this operator and this center performed? — Volume matters in structural heart procedures.
- What does my appendage anatomy look like, and are there any features that make implantation more challenging? — Certain appendage morphologies (such as "chicken wing" or very large appendages) can affect device selection and outcomes.
- What is the plan if a significant peri-device leak is found at 45 days? — Understanding the contingency plan is important.
- Am I also a candidate for surgical appendage closure if I need another cardiac procedure? — If you are facing valve surgery or a maze procedure for AFib, surgical closure of the appendage at the same time may be a better option.
These are not confrontational questions. Any interventional cardiologist performing LAAC should welcome them. If the answers feel vague or rushed, that is information in itself.
When a Second Opinion on Watchman or LAAC Makes a Difference
I have reviewed cases where patients were offered a Watchman device without a thorough exploration of why their blood thinner was problematic — or where the bleeding event that triggered the referral was actually manageable with a medication change. I have also seen the opposite: patients who were clearly struggling on anticoagulation but were never told that LAAC existed as an option.
The decision to implant a permanent device in your heart deserves careful, individualized analysis. That means reviewing your echocardiographic imaging, your bleeding and stroke risk scores, your medication history, your other cardiac conditions, and your goals. It means looking at the whole picture, not just the appendage.
If you are facing a decision about the Watchman device or left atrial appendage closure and want an independent, expert perspective, a WhiteGloveMD second opinion can help. Our team — which includes fellowship-trained structural heart specialists and cardiovascular surgeons — will review your records, imaging, and clinical data and provide a clear, written assessment of whether LAAC is the right strategy for you, whether alternative approaches should be considered, and what questions to bring back to your treating physician. You do not have to make this decision alone, and you should not have to make it without all the information.